RESUMEN
OBJECTIVE: The aim of this study was to determine the frequency of cryoglobulinemia and associated symptoms in transfusion-dependent thalassemia patients at high risk for HCV infection. METHODS: A controlled epidemiological study was used to evaluate the prevalence of clinical, biochemical and immunological abnormalities in a group of 264 HCV-positive and 106 HCV-negative transfusion-dependent thalassemia patients. Haematologic and hepatic function tests were performed according to standard methods. HCV-RNA was detected by PCR analysis. RESULTS: The significant presence of cryoglobulinemia and associated symptoms (purpura, vasculitis, arthritis, asthenia, proteinuria), serum autoantibodies (SMA, anti-GOR, ANA, LKM), low complement and rheumatoid factor were found in HCV-positive compared with HCV-negative patients. CONCLUSIONS: This study demonstrates the role of HCV in inducing cryoglobulinemia and immunological disorders in transfusion-dependent thalassemia patients. HCV infection and associated immune abnormalities are a new clinical aspect of, and deserve particular attention due to their high frequency in, transfusion-dependent thalassemia patients.
Asunto(s)
Crioglobulinemia/etiología , Hepatitis C/etiología , Reacción a la Transfusión , Talasemia beta/complicaciones , Adolescente , Biomarcadores , Niño , Preescolar , Crioglobulinemia/epidemiología , Hepatitis C/epidemiología , Humanos , Lactante , Masculino , Prevalencia , Factores de Riesgo , Talasemia beta/fisiopatología , Talasemia beta/terapiaRESUMEN
Catalase was investigated as a possible catalyst of the electrochemical reduction of oxygen on glassy carbon electrodes. The presence of catalase dissolved in solution only provoked a moderate current increase, which was fully explained by the catalase-catalysed disproportionation of hydrogen peroxide (Scheme I). When catalase was adsorbed from dimethylsulfoxide on the surface of electrodes that did not undergo any electrochemical pre-treatment (EP), catalase efficiently catalysed oxygen reduction via direct electron transfer from the electrode (Scheme II). The results are discussed with respect to the electrode surface properties and the enzyme structure.
Asunto(s)
Catalasa/metabolismo , Electroquímica/métodos , Enzimas Inmovilizadas/metabolismo , Adsorción , Carbono , Catalasa/química , Catálisis , Dimetilsulfóxido/química , Propiedades de SuperficieRESUMEN
The presence of HBV DNA was assessed in the serum samples from 878 HBsAg negative Sardinian blood donors. They were composed of 481 (55%) donors selected because of abnormal serum alanine aminotransferase (ALT) levels during routine testing of their blood donation, and of 397 donors (45%) selected on the basis of normal serum ALT activities. HBV DNA sequences were detected in 37 (7.7%) out of 481 subjects with abnormal ALT and in 2 (0.5%) out of 397 subjects with normal ALT. Anti-HBc was detected in 199 (41%) of the 481 subjects with abnormal ALT and in 81 (20%) out of 397 subjects with normal ALT. Among the 39 subjects positive for serum HBV DNA, 12 (31%) were positive for anti-HBc, while 27 (69%) were negative for all serological HBV markers. These data show in Sardinia, where HBV infection is endemic, there is a high frequency of HBsAg negative HBV DNA positive individuals in whom multiplication of HBV may occur without conventional serological HBV markers, suggesting the possible existence of HBV-like viruses which may be responsible for some of the presumed non-A non-B hepatitis.
Asunto(s)
Donantes de Sangre , ADN Viral/sangre , Antígenos de Superficie de la Hepatitis B/sangre , Virus de la Hepatitis B/genética , Adulto , Autorradiografía , Secuencia de Bases , Femenino , Anticuerpos contra la Hepatitis B/sangre , Antígenos del Núcleo de la Hepatitis B/inmunología , Humanos , Italia , Masculino , Persona de Mediana Edad , Datos de Secuencia Molecular , Hibridación de Ácido Nucleico , Transaminasas/sangreRESUMEN
In order to determine whether the immunological abnormalities described in intravenous drug addicts (IDA), are due to HIV infection, other viral infections or to the abuse of narcotic drugs, we studied the T lymphocyte subsets and serological markers of infection with hepatitis B and delta virus, cytomegalovirus and Epstein Barr virus, in 49 IDA. The immunological and serological features of IDA were compared with the control group, made up of 20 healthy subjects. In intravenous drug abusers we found a significant increase in the number of total lymphocytes (P less than 0.01), T-lymphocytes (P less than 0.05), T-suppressor cells (P less than 0.05), and serum IgG levels (P less than 0.0001) as compared with the control group. The prevalence of serological markers of infection with hepatitis B virus, hepatitis delta virus, cytomegalovirus and Epstein Barr virus was significantly higher in IDA as compared with the controls. In conclusion our study demonstrates that T-lymphocyte subsets in IDA seronegative for HIV infection are characterized by an enhancement of peripheral lymphocyte cells with a normal OKT4/OKT8 ratio.
Asunto(s)
Seropositividad para VIH , Dependencia de Heroína/inmunología , Inmunoglobulinas/análisis , Linfocitos/inmunología , Virosis/inmunología , Adulto , Infecciones por Citomegalovirus/inmunología , Ensayo de Inmunoadsorción Enzimática , Femenino , Hepatitis B/inmunología , Hepatitis D/inmunología , Infecciones por Herpesviridae/inmunología , Herpesvirus Humano 4 , Humanos , Recuento de Leucocitos , Masculino , Linfocitos T/inmunología , Linfocitos T Reguladores/inmunologíaRESUMEN
Hepatitis B virus (HBV) DNA sequences were assessed in 26 patients with acute type B hepatitis, using dot-blot hybridization technique from peripheral blood mononuclear cells (PBMC), during different phases of the illness. At clinical presentation, 15% of patients showed HBV-DNA sequences in PBMC, while serum HBV-DNA was detected in 58% of patients. During clinical improvement 50% of patients had HBV-DNA in PBMC but only 11.5% were positive for serum HBV-DNA. Twenty-three (88.5%) patients recovered and cleared HBV-DNA from serum and from PBMC; three (11.5%) patients with acute hepatitis progressing to chronicity showed persistently HBV-DNA sequences in serum and in PBMC. In conclusion, our study shows that HBV-DNA sequences may be found in PBMC, transiently in patients with acute hepatitis followed by recovery, persistently in patients with acute hepatitis progressing to chronicity.
Asunto(s)
Virus de la Hepatitis B/genética , Hepatitis B/genética , Linfocitos/microbiología , Enfermedad Aguda , Adolescente , Adulto , Secuencia de Bases , Biomarcadores/sangre , ADN Viral/sangre , ADN Viral/genética , Femenino , Hepatitis B/sangre , Hepatitis B/microbiología , Anticuerpos contra la Hepatitis B/análisis , Antígenos de la Hepatitis B/análisis , Hepatitis Crónica/sangre , Hepatitis Crónica/genética , Hepatitis Crónica/microbiología , Humanos , Masculino , Persona de Mediana Edad , Hibridación de Ácido NucleicoAsunto(s)
Complejo Relacionado con el SIDA/epidemiología , Síndrome de Inmunodeficiencia Adquirida/epidemiología , Seropositividad para VIH/epidemiología , Complejo Relacionado con el SIDA/inmunología , Adolescente , Adulto , Donantes de Sangre , Ensayo de Inmunoadsorción Enzimática , Femenino , Seropositividad para VIH/inmunología , Humanos , Italia , Fallo Renal Crónico/complicaciones , Masculino , Trastornos Relacionados con Sustancias/complicaciones , Linfocitos T/inmunología , Talasemia/complicacionesRESUMEN
Despite recent advances in the treatment of chronic viral hepatitis, therapy of chronic hepatitis D is not yet satisfactory. The only option currently available is interferon-alpha (IFN), whose efficacy is related to the dose and duration of treatment. However, the rate of sustained hepatitis D virus (HDV) clearance after a 1-year course with high doses of standard IFN is low. Better results have recently been reported with pegylated IFN both in IFN-naïve and in previous nonresponders to standard IFN, suggesting the use of pegylated IFN as a first-line therapy in chronic hepatitis D. Nucleoside analogues that inhibit hepatitis B virus (HBV) are ineffective against HDV and combination therapy with lamivudine or ribavirin has not shown significant advantages over monotherapy with either standard or pegylated IFN. Because the ultimate goal of treatment is eradication of both HDV and HBV, in responders IFN therapy should be continued as long as possible until the loss of hepatitis B surface antigen, adjusting the dose to patient tolerance. However, because side-effects are common, continuous monitoring is mandatory. Although the first results obtained with pegylated IFN have been encouraging, the rate of sustained virological response is still low and the rate of relapse high, emphasizing the need for developing novel classes of antivirals specifically interfering with the life cycle of this unique virus.
Asunto(s)
Hepatitis D Crónica/tratamiento farmacológico , Hepatitis D Crónica/virología , HumanosRESUMEN
Eye examination was performed in a series of 53 patients whose mean age was 19.5 years (range from 11 to 25 years), affected from Cooley's disease, in treatment with transfusions and desferrioxamine in subcutaneous infusion. The most frequent ocular change was fundus mottling appearance like "leopard skin" (15%). We found also lens opacity (11%), drusen (7%), retinal venous tortuosity (5%), without impairment of visual acuity. The pathogenic factors of the ocular change are related to abnormality of iron metabolism. These results suggest that the involvement of desferrioxamine to remove iron from the eyeball is relatively small.
Asunto(s)
Oftalmopatías/etiología , Talasemia/complicaciones , Adolescente , Adulto , Transfusión Sanguínea , Catarata/etiología , Niño , Deferoxamina/uso terapéutico , Femenino , Humanos , Masculino , Enfermedades de la Retina/etiología , Drusas Retinianas/etiología , Talasemia/tratamiento farmacológicoRESUMEN
The high endemicity of hepatitis B virus (HBV) infection and liver disease in Sardinia led us to assess the occurrence of HBV DNA in 1,411 sera of two selected groups of hepatitis B surface antigen (HBsAg)-negative blood donors: 793 with abnormal serum alanine aminotransferase (ALT) and 618 with normal serum ALT values (determined during routine testing of their blood donation). HBV DNA sequences were detected by dot-blot hybridization in 68 of 793 subjects (9%) with abnormal ALT but only in three of 618 subjects (0.5%) with normal ALT. HBV-core antibody (anti-HBc) was detected in 338 of 793 subjects (43%) with abnormal ALT as well as in 125 of 618 subjects (20.2%) with normal ALT. Among the 71 subjects positive for serum HBV DNA, 22 (31%) were positive for anti-HBc, while 49 (69%) were negative for all serologic markers of HBV infection. Thus, a high frequency of anti-HBc in apparently healthy HBsAg-negative individuals and a high prevalence of serum HBV DNA in the absence of immunologic markers of HBV infection suggest the existence of genetic variants of HBV that may be responsible for some of the presumed NANB hepatitis encountered in Sardinia and possibly other areas of high endemicity for HBV.
Asunto(s)
Donantes de Sangre , ADN Viral/sangre , Antígenos de Superficie de la Hepatitis B/análisis , Virus de la Hepatitis B/genética , Adolescente , Adulto , Alanina Transaminasa/sangre , Anticuerpos Monoclonales , ADN Viral/aislamiento & purificación , Femenino , Anticuerpos Antihepatitis/análisis , Humanos , Italia , Masculino , Persona de Mediana Edad , Hibridación de Ácido NucleicoRESUMEN
In a large population of patients, chronic hepatitis delta virus (HDV) infection was usually associated with absence of hepatitis B virus (HBV) replication. However, acute HDV superinfection progressing to chronic HDV infection in two hepatitis B e antigen (HBeAg)-positive HBV carriers and coinfection in two other patients who progressed to chronic HBV (HBeAg-positive) and HDV infection was associated with continuing high-level HBV replication for several years. Thus HDV infection does not always inhibit HBV replication. The hypothesis that the different effects of HDV coinfection and superinfection on HBV replication may stem from variability in the capacity of the host to produce and respond to interferon is discussed.
Asunto(s)
Hepatitis B/complicaciones , Hepatitis D/complicaciones , Enfermedad Aguda , Adolescente , Adulto , Antígenos Virales/aislamiento & purificación , ADN Viral/aislamiento & purificación , Femenino , Hepatitis B/microbiología , Virus de la Hepatitis B/aislamiento & purificación , Virus de la Hepatitis B/fisiología , Hepatitis D/microbiología , Hepatitis Crónica/complicaciones , Hepatitis Crónica/microbiología , Humanos , Masculino , Persona de Mediana Edad , Replicación ViralRESUMEN
Serum samples from 1,765 consecutive Sardinian blood donors, negative for hepatitis B surface antigen (HBsAg) and for antibodies to human immunodeficiency virus (HIV) (anti-HIV), were evaluated for the presence of antibodies to hepatitis C virus (anti-HCV) by second-generation ELISA. Anti-HCV was detected in 25 (1.45%) of the 1,765 donors examined. Anti-HCV was found in 15 of the 1,690 (0.9%) donors with normal alanine aminotransferase (ALT) and in 10 of the 75 (13%) donors with elevated ALT (P < 0.0001). Of the 15 anti-HCV-positive donors with normal ALT, only five (33%) were confirmed to be positive by second-generation RIBA, six (40%) were indeterminate, while four (27%) were RIBA negative. HCV RNA, as detected by polymerase chain reaction (PCR) using a set of primers from the 5'-noncoding region, was found in six of the 15 (40%) donors with normal ALT, including five RIBA positive and one indeterminant. Of the 10 anti-HCV-positive donors with elevated ALT, all were RIBA positive and eight (80%) had detectable HCV RNA. Thus, among ELISA-reactive donors, those with elevated ALT had a significantly higher probability of being positive for second-generation RIBA and HCV RNA compared to those with normal ALT levels (P = 0.028). None of the 65 donors with elevated ALT but negative for anti-HCV by ELISA had detectable serum HCV RNA, as compared to eight of 10 anti-HCV ELISA-positive donors (P < 0.0001). However, although negative for HBsAg, 12 of the 65 (18%) had serum HBV DNA by PCR.(ABSTRACT TRUNCATED AT 250 WORDS)
Asunto(s)
Alanina Transaminasa/sangre , Donantes de Sangre , Hepacivirus/inmunología , Anticuerpos Antihepatitis/sangre , Hepatitis C/epidemiología , Adolescente , Adulto , Secuencia de Bases , ADN Viral/sangre , Ensayo de Inmunoadsorción Enzimática , Femenino , Hepacivirus/genética , Virus de la Hepatitis B/genética , Hepatitis C/inmunología , Anticuerpos contra la Hepatitis C , Humanos , Italia/epidemiología , Masculino , Persona de Mediana Edad , Datos de Secuencia Molecular , Reacción en Cadena de la Polimerasa , ARN Viral/sangre , Radioinmunoensayo , Sensibilidad y EspecificidadRESUMEN
An echocardiographic study was performed in 21 young patients with thalassemia major (TM, age 16-22 years), with no cardiac symptoms, and in 24 age-matched normals (N) at rest and during sitting bicycle exercise (EX). All TM were receiving blood transfusions regularly to maintain hemoglobin level above 11 g/dl and subcutaneous infusion of desferrioxamine (40 mg/Kg/day) to reduce hemosiderosis. At rest, in comparison to N, TM showed a significant increase in LV end-diastolic dimension (EDD), septal, posterior wall thickness and mass, whereas wall thickness to EDD ratio and LV fractional shortening (FS) were not different. Stress echocardiography was recorded with success in 90% of TM and 83% of N. During EX, FS increased progressively with increase of heart rate in both groups, though the increase of FS was lower in TM. Thus, asymptomatic young patients with thalassemia major, under well transfusion-chelation therapy, showed cardiac changes from volume overload. LV systolic function, normal at rest, was moderately impaired during exercise test.
Asunto(s)
Ecocardiografía , Hemodinámica , Talasemia/fisiopatología , Adolescente , Adulto , Prueba de Esfuerzo , Humanos , Masculino , DescansoRESUMEN
During an 8-year prospective study of post-transfusion hepatitis conducted at the Thalassemic Center of Cagliari (Italy), including 135 newly diagnosed thalassemic children on long-term transfusion maintenance, 83 children (61%) developed non-A, non-B hepatitis (NANBH). Resolution of NANBH was observed in 17 (20%) cases, and chronicity in 57 (69%), whereas the remaining 9 (11%) experienced one or two additional bouts of acute NANBH. Of the 83 children with NANBH, 75 (90%) showed anti-hepatitis C virus (HCV) seroconversion when tested by second-generation enzyme-linked immunosorbent assay (ELISA), whereas first-generation ELISA showed anti-HCV in only 59 (71%) cases (p = 0.003). Moreover, the newly developed assay allowed an earlier detection of anti-HCV response in most of the patients who seroconverted by both assays, reducing significantly the mean onset-seroconversion interval (5 +/- 9.4 weeks vs. 14.5 +/- 20.8 weeks, p < 0.05). It was significantly more sensitive for the identification of HCV infection, not only in resolving NANBH, but also in NANBH progressing to chronicity (79 vs. 35%, respectively, p = 0.008; and 93 vs. 79%, p = 0.028). The pattern of antibody response with first-generation assay was characterized by clearance of anti-HCV with time, in most of the patients who recovered, and by persistence of anti-HCV in the majority of those who progressed to chronicity, whereas second-generation ELISA usually showed persistence of anti-HCV over time, regardless to the outcome of the disease.(ABSTRACT TRUNCATED AT 250 WORDS)
Asunto(s)
Transfusión de Componentes Sanguíneos/efectos adversos , Anticuerpos Antihepatitis/sangre , Hepatitis C/inmunología , Talasemia beta/terapia , Enfermedad Aguda , Alanina Transaminasa/sangre , Distribución de Chi-Cuadrado , Preescolar , Enfermedad Crónica , Ensayo de Inmunoadsorción Enzimática , Femenino , Estudios de Seguimiento , Hepacivirus/inmunología , Hepatitis C/diagnóstico , Hepatitis C/enzimología , Hepatitis C/etiología , Anticuerpos contra la Hepatitis C , Humanos , Lactante , Masculino , Estudios Prospectivos , Sensibilidad y EspecificidadRESUMEN
Ten patients with evidence of continuing HDV replication were treated with lymphoblastoid alpha-interferon and eight more were followed as a non-randomized control group. Four out of eight patients who completed one year of follow-up had cleared HDV-RNA from the serum whilst none of the control group did so. In these four responding cases there was a transient increase in transaminase levels during treatment and in two, this was followed by improvement. One patient also cleared HBV and seroconverted to anti-HBs (antibody to hepatitis B surface antigen--HBsAg). In one patient with sustained loss of HDV, recurrence of HDV infection was detected 18 months after completion of treatment. These data suggest that alpha-interferon can inhibit HDV replication in the short term but relapse after one to two years may occur. Inhibition of HDV-RNA is associated with improvement in the inflammatory liver disease and now larger studies are required to determine whether it influences survival.
Asunto(s)
Hepatitis D/terapia , Interferón Tipo I/uso terapéutico , Adulto , Antígenos Virales/análisis , Antígenos Virales/inmunología , Niño , Enfermedad Crónica , ADN Viral/análisis , Femenino , Antígenos de la Hepatitis B/análisis , Virus de la Hepatitis B/aislamiento & purificación , Hepatitis D/diagnóstico , Virus de la Hepatitis Delta/genética , Virus de la Hepatitis Delta/inmunología , Antígenos de Hepatitis delta , Humanos , Masculino , Persona de Mediana Edad , ARN Viral/análisisRESUMEN
To define the relationship between pre-core hepatitis B virus mutants and the long-term outcome of chronic hepatitis B virus infection, we monitored the type of circulating pre-core hepatitis B virus-DNA by polymerase chain reaction and sequencing in 41 selected chronic HBsAg carriers with extensive follow up. They included 12 HBeAg-positive patients with chronic hepatitis, who seroconverted to anti-HBe during follow up and 29 anti-HBe positive patients, 23 of whom had chronic hepatitis and six acute severe exacerbation occurring spontaneously (three cases) or during antitumor chemotherapy (three cases). In the presence of HBeAg, all showed prevalence of the pre-core wild type along with high levels of viral replication and elevated alanine aminotransferase. Anti-HBe seroconversion was accompanied by a dramatic reduction of hepatitis B virus replication and normalization of alanine aminotransferase in all, except one, and by the emergence of mutated strains with a pre-core stop codon (point mutation G to A at nt 1896) that replaced the wild type in seven of the 12. Of the seven who harboured the pre-core mutant, three continued to show normal alanine aminotransferase during subsequent follow up, three had mild alanine aminotransferase elevation and one had an acute short-lived reactivation after 4.4 years of normal alanine aminotransferase. The five cases who continued to show prevalence of wild type in spite of anti-HBe seroconversion all revealed persistently normal alanine aminotransferase.(ABSTRACT TRUNCATED AT 250 WORDS)
Asunto(s)
Virus de la Hepatitis B/genética , Hepatitis B/virología , Hepatitis Crónica/virología , Proteínas del Núcleo Viral/genética , Adulto , Alanina Transaminasa/sangre , Secuencia de Bases , Niño , Femenino , Estudios de Seguimiento , Hepatitis B/sangre , Hepatitis B/patología , Antígenos de Superficie de la Hepatitis B/sangre , Antígenos e de la Hepatitis B/sangre , Hepatitis Crónica/sangre , Hepatitis Crónica/patología , Humanos , Masculino , Persona de Mediana Edad , Datos de Secuencia Molecular , Mutación Puntual , Reacción en Cadena de la Polimerasa , Pronóstico , Estudios Prospectivos , Sensibilidad y EspecificidadRESUMEN
The purpose of this study was to determine whether interferon-alfa (IFN-alpha) therapy benefits patients with transfusion-dependent thalassemia and chronic active hepatitis C, and whether their iron burden modifies the response to this therapy. We conducted a controlled trial of recombinant IFN-alpha (3 million units per square meter of body surface area, three times a week for 15 months) in 65 patients with thalassaemia major and chronic active hepatitis C; 14 of them were untreated control subjects. In 21 of the 51 treated patients, alanine aminotransferase values returned to normal within 6 months, and hepatitis C virus ribonucleic acid was no longer detected in serum; no changes were detected among control subjects. The response to IFN-alpha therapy was inversely related (p < 0.002) to the liver iron burden as assessed by atomic absorption, the histologic semiquantitative method, or both methods. During 3 years of follow-up, two responder patients had relapses. We conclude that IFN-alpha represents a useful therapeutic option for children with transfusion-dependent thalassemia and chronic active hepatitis C with a mild to moderate iron burden.
Asunto(s)
Hemocromatosis/fisiopatología , Hepatitis C/terapia , Hepatitis Crónica/terapia , Interferón-alfa/uso terapéutico , Talasemia beta/terapia , Adolescente , Adulto , Niño , Ferritinas/sangre , Hemocromatosis/etiología , Hepatitis C/etiología , Hepatitis Crónica/etiología , Humanos , Interferón-alfa/efectos adversos , Hierro/análisis , Hígado/química , Reacción a la Transfusión , Resultado del Tratamiento , Talasemia beta/sangre , Talasemia beta/complicacionesRESUMEN
We investigated the course of distinct episodes of acute non-A, non-B (NANB) hepatitis in three polytransfused thalassaemic children. In each case, the first episode was associated with the appearance of serum hepatitis C virus (HCV) RNA and anti-HCV seroconversion. The second episode was accompanied by the reappearance of HCV viraemia, which in two patients was due to reinfection with a different HCV strain and in the third could be the result of either reactivation of primary infection or reinfection with a new but closely related strain. Thus HCV infection may not induce protective immunity, which has implications for vaccine development.
Asunto(s)
Hepatitis C/etiología , Talasemia/complicaciones , Reacción a la Transfusión , Viremia/etiología , Enfermedad Aguda , Preescolar , Hepacivirus/clasificación , Humanos , Lactante , Recurrencia , Talasemia/terapiaRESUMEN
Ongoing hepatitis B virus replication in the presence of antibody to HBeAg can be observed in patients with active liver disease. These forms of chronic hepatitis B have been described as having a poor prognosis. We have conducted a randomized controlled trial to assess the efficacy of lymphoblastoid interferon-alpha in 60 patients with antibody to HBeAg and hepatitis B virus DNA-positive chronic hepatitis. Patients received 5 million U/m2 interferon three times a week for 6 mo, or no treatment. Final evaluation 18 mo after randomization showed hepatitis B virus DNA negativity and ALT normalization in 53% of treated patients and in 17% of controls (p less than 0.01). The probability of sustained hepatitis B virus DNA loss was significantly higher in treated patients than in controls (p less than 0.005). Blinded histological assessment revealed improvement in 50% of treated patients compared with 33% of controls. Pretreatment hepatitis B virus DNA and aminotransferase levels and histological appearance were not predictive of response. The results of this trial indicated that marked reduction of viral replication in serum and remission of liver damage can be obtained with lymphoblastoid interferon in about 50% of patients with HBeAg antibody- and HBV DNA-positive chronic hepatitis. This rate of response is higher than that reported previously.
Asunto(s)
Antígenos e de la Hepatitis B/análisis , Hepatitis B/terapia , Interferón gamma/uso terapéutico , Adulto , Biopsia , Enfermedad Crónica , ADN Viral/análisis , Femenino , Hepatitis B/inmunología , Hepatitis B/patología , Virus de la Hepatitis B/genética , Humanos , Interferón gamma/efectos adversos , Hígado/patología , MasculinoRESUMEN
To study the spread of human immunodeficiency virus type 1 (HIV-1) in Sardinia, we conducted a multicentre prospective study of the prevalence of antibody to HIV-1 (anti-HIV-1) in various populations during 1985-1989. The highest anti-HIV-1 prevalence (61.4%) was found in intravenous drug users. Anti-HIV-1 was found in 32% of haemophiliacs, 4.2% of thalassemics and less than 1% in the other groups. We conclude that control of HIV infection in Sardinia will require a major expansion of prevention and treatment programs for drug addiction.